title: [Eradication therapy of Helicobacter pylori--associated diseases: efficacy, safety, pharmacoeconomy].
authors.forename: V B
authors.initials: VB
authors.lastname: Grinevich
authors.forename: O A
authors.initials: OA
authors.lastname: Sablin
authors.forename: I V
authors.initials: IV
authors.lastname: Gubonina
authors.forename: V A
authors.initials: VA
authors.lastname: Dobrenko
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D017291:Clarithromycin / Q000191:economics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D009942:Organometallic Compounds; D054328:Proton Pump Inhibitors; D017291:Clarithromycin; C002791:bismuth tripotassium dicitrate